Canbro Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.00 M
- Paid Up Capital ₹ 7.00 M
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.60 Cr
- Revenue Growth %
- Net Worth 0.81%
- Total Assets 10.55%
About Canbro Pharmaceuticals
Canbro Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 June 2019 (Five years and eight months 17 days old ). Its registered office is in Karnal, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 M and a paid-up capital of Rs 7.00 M.
The company currently has active open charges totaling ₹1.60 Cr.
Manoj Malhotra, Parikshit Malhotra, Manish Kumar, and One other member serve as directors at the Company.
Company Details
- Location
Karnal, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304HR2019PTC080778
- Company No.
080778
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Canbro Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Malhotra  | Director | 07-Jun-2019 | Current |
| Parikshit Malhotra | Director | 07-Jun-2019 | Current |
| Manish Kumar | Additional Director | 22-Apr-2024 | Current |
| Joginder Rawat | Additional Director | 22-Apr-2024 | Current |
Financial Performance of Canbro Pharmaceuticals.
Canbro Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth moved up by a moderate rise of 0.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Canbro Pharmaceuticals?
Unlock access to Canbro Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹16.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2019 | Others | ₹6.00 M | Open |
| 31 Dec 2019 | Others | ₹1.00 Cr | Open |
How Many Employees Work at Canbro Pharmaceuticals?
Unlock and access historical data on people associated with Canbro Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Canbro Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Canbro Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
